- KYPROLIS® (carfilzomib) is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone or with daratumumab and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. ... Read More
KRd vs Rd study design
A superiority study compared KRd to Rd alone1
Phase 3, randomized, open-label study (N = 792) in patients with relapsed or refractory multiple myeloma who had received 1 to 3 lines of therapy1
Superiority study: KRd vs Rd1,2
Inclusion criteria allowed for diverse patient types
Key inclusion criteria1,2
- Adults with relapsed or refractory multiple myeloma
- 1 to 3 prior treatments
- Achieved a response in at least 1 prior regimen
- Adequate hepatic, hematologic, and renal function (CrCL ≥ 50 mL/min) at screening
Key exclusion criteria1,2
- PD while on bortezomib*
- If previously treated with Rd: PD during first 3 months of any treatment or PD at any time if Rd was the most recent treatment
- Intolerance to lenalidomide or dexamethasone treatment
- Grade 3 or 4 peripheral neuropathy (or Grade 2 with pain) within 14 days prior to randomization
- NYHA Class III or IV heart failure
The patients studied in the KRd vs Rd trial may resemble the patients in your practice
Select patient demographics and baseline characteristics1
Characteristic | KRd (n = 396) | Rd (n = 396) |
---|---|---|
Age | ||
Median, years (min, max) | 64 (38, 87) | 65 (31, 91) |
ECOG performance status, n (%) | ||
0 | 165 (42) | 175 (44) |
1 | 191 (48) | 186 (47) |
2 | 40 (10) | 35 (9) |
ISS stage at study baseline, n (%) | ||
I | 167 (42) | 154 (39) |
II | 148 (37) | 153 (39) |
III | 73 (18) | 82 (21) |
Risk factors | ||
CrCL, mL/min, median (min, max) | 79 (39, 212) | 79 (30, 208) |
30 to < 50, n (%) | 19 (5) | 32 (8) |
50 to < 80, n (%) | 185 (47) | 170 (43) |
Prior regimens at baseline2
Prior regimens at baseline | KRd (n = 396) | Rd (n = 396) |
---|---|---|
Number of prior regimens, median (range) | 2 (1-3)* | 2 (1-3)* |
Prior therapies, n (%) | ||
Transplantation | 217 (55) | 229 (58) |
Bortezomib | 261 (66) | 260 (66) |
Nonresponsive to prior bortezomib | 60 (15) | 58 (15) |
Lenalidomide | 79 (20) | 78 (20) |
Any IMiD | 233 (59) | 229 (58) |
Refractory to prior IMiD in any prior regimen | 85 (22) | 88 (22) |
Bortezomib and IMiD | 146 (37) | 139 (35) |
Nonresponsive to prior bortezomib and refractory to prior IMiD | 24 (6) | 27 (7) |